| Field | Specification |
|---|---|
| Mfr No | |
| Species |
The PC-9 cell line is derived from a human lung adenocarcinoma, a subtype of non-small cell lung cancer (NSCLC). This cell line is particularly notable for harboring an activating mutation in the EGFR gene, specifically the exon 19 deletion (E746_A750del), which is a common driver mutation in NSCLC. This alteration makes PC-9 an invaluable model for studying the biology of EGFR-driven cancers and evaluating the efficacy of tyrosine kinase inhibitors (TKIs) like gefitinib and erlotinib, which specifically target this pathway.
PC-9 cells have been extensively used in research focused on resistance mechanisms to EGFR TKIs, particularly the emergence of secondary mutations like T790M. These studies have informed the development of third-generation inhibitors such as osimertinib, which target both the primary EGFR mutation and resistance-associated alterations. The cell line also exhibits sensitivity to other inhibitors targeting downstream signaling pathways, including those involved in PI3K/AKT and MAPK signaling cascades, underscoring its utility in translational cancer research.
In addition to its genetic and pharmacological attributes, PC-9 has been incorporated into high-throughput drug screening programs, facilitating the identification of compounds with selective activity against EGFR-mutated NSCLC. The line's well-characterized genomic landscape and consistent phenotypic behavior in vitro make it a cornerstone for both basic and applied lung cancer research, particularly in the context of targeted and combination therapy.
—
Tumorigenic: Yes
- cultureMedium: RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a)
- supplements: Supplement the medium with 10% FBS
- dissociationReagent: Accutase
- subculturing: Gather the suspension cells in a 15 ml tube and gently wash the adherent cells with PBS lacking calcium and magnesium (use 3-5 ml for T25 flasks and 5-10 ml for T75 flasks). Apply Accutase (1-2 ml for T25 flasks, 2.5 ml for T75 flasks) ensuring full coverage of the cell layer. Allow the cells to incubate at 37°C for 10-15 minutes. Following incubation, combine and centrifuge both the suspension and adherent cells. After centrifugation, carefully resuspend the cell pellet and transfer the cell suspension into new flasks containing fresh medium.
- fluidRenewal: 1 to 2 times per week
- freezeMedium: As a cryopreservation medium, use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress.
10%
OFF
15%OFF
20%
OFF
$50
OFF
FREE
SAMPLE
